HomeStrategyA Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund... Strategy A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs Strategy October 7, 2026 0 5 FacebookXPinterestWhatsApp The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale. FacebookXPinterestWhatsApp Cody Previous articleAffirm partners with Ant International’s Antom to bring pay-over-time to US customersNext articleAfter $21M assessment uproar, Brickell association says contractor overbilled, left work undone RELATED ARTICLES Strategy What will happen to Paramount+ and HBO Max under the new Skydance? Strategy Jaguar finally launched its new EV. Here’s what people are saying Strategy AI chatbots are ignoring this prompt from wealthy users, in a phenomenon called ‘adversarial delegation’ Strategy Want to Be More Likable? Just Say These 5 Magic Phrases. Must Read US venture deal value reaches record $515.8B as exits fail to keep pace Tech Google debuts SynthID Detector tool for flagging AI-generated content, but it’s far from perfect Tech At WebexOne, Cisco’s Jeetu Patel argues the agent era will be won on context, cost and control Tech Samsung forecasts world record-breaking $80B profit Tech After $21M assessment uproar, Brickell association says contractor overbilled, left work undone Real Estate